查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1373929

支氣管擴張藥物市場，按藥物類別、給藥途徑、配銷通路、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Bronchiectasis Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 306 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022年支氣管擴張藥物市場規模為4.8171億美元，2023年至2030年複合CAGR為5.1%。

支氣管擴張藥物市場-市場動態

人們對這種經常被低估的疾病的認知不斷提高，推動了市場需求

醫學知識和診斷能力的進步導致支氣管擴張病例的識別增加。此外，人口老化和慢性呼吸系統疾病的激增增加了對更有效治療解決方案的需求。這種認知的提高以及患者人數的增加，促使製藥公司和研究人員分配資源來制定增強的支氣管擴張治療策略。這些努力背後的驅動力是致力於改善支氣管擴張患者的福祉，同時減輕反覆感染和相關症狀的負擔。

支氣管擴張藥物市場 - 關鍵見解

根據研究分析師提供的見解，預計2023年至2030年的預測期內，全球支氣管擴張藥物市場的年成長率約為 5.1%。

支氣管擴張藥物產業有望大幅擴張，這主要是由於人們越來越認知到這種經常未被發現的醫療狀況。

就藥物類別分類而言，預計抗生素在2022年佔據市場主導地位。

基於給藥途徑的細分，口服藥物成為2022年的主導類別。

從地理上看，北美地區在2022年的創收方面處於領先地位。

支氣管擴張藥物市場-細分分析：

全球支氣管擴張藥物市場是圍繞著藥物類別、給藥途徑、配銷通路和地區等關鍵因素而建構的。

在藥物類別分類方面，該市場分為四個不同的部分：抗生素、黏液溶解劑、支氣管擴張劑和抗發炎藥物。值得注意的是，抗生素在這一分類中處於領先地位。它們在支氣管擴張治療中的重要性在於它們在控制和預防肺部感染復發方面的作用，肺部感染是與此疾病相關的常見併發症。抗生素有助於瞄準和根除導致這些感染的微生物，最終改善患者症狀、肺功能和整體生活品質。

支氣管擴張藥物市場 - 地理洞察

從地理來看，這個市場橫跨北美、拉丁美洲、歐洲、亞太、中東和非洲等地區。在這些地區，各國在推動商業活力方面發揮關鍵作用。

多種因素共同刺激了北美對支氣管擴張藥物的需求增加。首先，該地區人口老化越來越容易罹患慢性呼吸系統疾病，包括支氣管擴張。其次，診斷專業知識和醫療保健從業人員知識的進步導致診斷更加準確和及時，大幅增加了對這些藥物的需求。

支氣管擴張藥物市場-競爭格局：

支氣管擴張藥物市場的特點是批准用於這種疾病的專門治療方法的選擇有限。領先的製藥公司提供一些主要的治療選擇。然而，該領域在專門藥物方面受到一定限制，治療主要依靠重新利用的抗生素、支氣管擴張劑和黏液溶解劑。這種限制為新藥的開發創造了一個利基市場，因為該公司探索目的是解決支氣管擴張的根本原因並改善患者預後的創新療法。這為該行業的成長和進步帶來了光明的前景。

目錄

第1章 支氣管擴張藥物市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘錄
    • 依藥物類別分類的支氣管擴張藥物市場摘錄
    • 依給藥途徑分類的支氣管擴張藥物市場摘錄
    • 依配銷通路分類的支氣管擴張藥物市場摘錄
    • 依國家分類的支氣管擴張藥物市場摘錄
    • 依地區分類的支氣管擴張藥物市場摘錄
  • 競爭洞察

第3章 支氣管擴張藥物主要市場趨勢

  • 支氣管擴張藥物市場促進因素
    • 市場促進因素的影響分析
  • 支氣管擴張藥物市場限制
    • 市場限制影響分析
  • 支氣管擴張藥物市場機會
  • 支氣管擴張藥物市場未來趨勢

第4章 支氣管擴張藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 支氣管擴張藥物市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 支氣管擴張藥物市場格局

  • 2022年支氣管擴張藥物市佔率分析
  • 細分資料：按主要製造商
    • 既有參與者分析
    • 新興參與者分析

第7章 支氣管擴張藥物市場 - 依藥物類別

  • 概述
    • 依藥物類別分類的細分市場佔有率分析
    • 抗生素
    • 黏液溶解劑
    • 支氣管擴張劑
    • 抗發炎劑

第8章 支氣管擴張藥物市場 - 依給藥途徑

  • 概述
    • 依給藥途徑分類的細分市佔率分析
    • 口服
    • 吸入
    • 靜脈

第9章 支氣管擴張藥物市場 - 依配銷通路

  • 概述
    • 依配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第10章 支氣管擴張藥物市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美支氣管擴張藥物主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依藥物類別）
    • 北美市場規模與預測（依管理途徑）
    • 北美市場規模和預測（依配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲支氣管擴張藥物主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（依藥物類別）
    • 歐洲市場規模與預測（依管理途徑）
    • 歐洲市場規模和預測（依配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區支氣管擴張藥物主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模和預測（依藥物類別）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模和預測（依配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲支氣管擴張藥物主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（依藥物類別）
    • 拉丁美洲市場規模與預測（依管理途徑）
    • 拉丁美洲市場規模和預測（依配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲支氣管擴張藥物主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依藥物類別）
    • 中東和非洲市場規模及預測（依管理途徑）
    • 中東和非洲市場規模及預測（依配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第11章 主要供應商分析-支氣管擴張藥物產業

  • 競爭儀表板
  • 公司簡介
    • GlaxoSmithKline plc
    • Novartis AG
    • Pfizer Inc.
    • AstraZeneca plc
    • Boehringer Ingelheim International GmbH
    • Roche Holding AG
    • Teva Pharmaceutical Industries Ltd.
    • Bayer AG
    • Sanofi SA
    • Sunovion Pharmaceuticals Inc.
    • Mylan NV
    • Cipla Ltd.
    • Grifols SA
    • Insmed Incorporated
    • Arbor Pharmaceuticals LLC

第12章 360 度分析師視角

第13章 附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV1785

REPORT HIGHLIGHT

Bronchiectasis Drugs Market size was valued at USD 481.71 Million in 2022, expanding at a CAGR of 5.1 % from 2023 to 2030.

Pharmaceutical solutions designed for bronchiectasis address the challenges associated with this persistent lung condition, characterized by the inflammation and enlargement of the bronchial tubes. These medications are tailored to alleviate symptoms such as persistent coughing, excessive mucus production, and the susceptibility to recurring lung infections. Treatment typically includes the administration of antibiotics to combat or prevent infections, bronchodilators to expand air passages, and mucolytics to facilitate mucus clearance. The treatment approach is individualized to cater to the specific needs of each patient, with a primary focus on symptom management, infection prevention, and the enhancement of overall lung function, ultimately aiming to enhance the quality of life for those living with bronchiectasis.

Bronchiectasis Drugs Market- Market Dynamics

Rising awareness of this often-underdiagnosed condition propel market demand

Advances in medical knowledge and diagnostic capabilities have led to an uptick in the identification of bronchiectasis cases. Additionally, the aging demographic and the surge in chronic respiratory ailments have heightened the demand for more effective treatment solutions. This increased awareness, along with a growing patient population, has prompted pharmaceutical companies and researchers to allocate resources towards the development of enhanced strategies for managing bronchiectasis. A driving force behind these endeavors is the commitment to improving the well-being of bronchiectasis patients while lessening the burden of recurrent infections and associated symptoms.

Bronchiectasis Drugs Market- Key Insights

In line with the insights provided by our research analyst, the global market for Bronchiectasis Medications is anticipated to experience an approximate annual growth rate of 5.1% throughout the forecast period from 2023 to 2030.

The Bronchiectasis Drugs sector is poised for substantial expansion, primarily driven by the increasing recognition of a medical condition that often goes undetected.

In terms of Drug Class categorization, Antibiotics were forecasted to dominate the market in the year 2022.

When considering the segmentation based on Route of Administration, Oral medications emerged as the leading category in 2022.

Geographically, North America took the lead in revenue generation in 2022.

Bronchiectasis Drugs Market- Segmentation Analysis:

The worldwide market for Bronchiectasis Medications is structured around key factors including Drug Class, Route of Administration, Distribution Channel, and Region.

When it comes to Drug Class categorization, this market is categorized into four distinct segments: Antibiotics, Mucolytics, Bronchodilators, and Anti-inflammatory agents. Notably, Antibiotics take the lead in this classification. Their significance in bronchiectasis therapy lies in their role in managing and preventing the reoccurrence of lung infections, a common complication associated with the condition. Antibiotics are instrumental in targeting and eradicating the microbes responsible for these infections, ultimately leading to improved patient symptoms, lung function, and overall quality of life.

Bronchiectasis Drugs Market- Geographical Insights

From a geographical perspective, this market spans across the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Within these regions, individual countries play a pivotal role in driving business dynamics.

Several factors have converged to stimulate the heightened demand for bronchiectasis medications in North America. Firstly, the region's aging population is increasingly susceptible to chronic respiratory ailments, including bronchiectasis. Secondly, the advancement of diagnostic expertise and healthcare practitioners' knowledge has led to more precise and timely diagnoses, significantly contributing to the demand for these medications.

Bronchiectasis Drugs Market- Competitive Landscape:

The bronchiectasis pharmaceutical market is distinguished by a limited selection of specialized treatments approved for this condition. Leading pharmaceutical companies offer some of the primary treatment options. Nevertheless, the field is somewhat limited in terms of specialized medications, with therapy predominantly relying on repurposed antibiotics, bronchodilators, and mucolytics. This limitation has created a niche for the development of new drugs, as companies explore innovative therapeutics designed to address the root causes of bronchiectasis and enhance patient outcomes. This presents promising prospects for growth and advancement within the sector.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BRONCHIECTASIS DRUGS MARKET KEY PLAYERS

  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Roche Holding AG
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Sanofi S.A.
  • Sunovion Pharmaceuticals Inc.
  • Mylan N.V.
  • Cipla Ltd.
  • Grifols S.A.
  • Insmed Incorporated
  • Arbor Pharmaceuticals LLC

GLOBAL BRONCHIECTASIS DRUGS MARKET, BY DRUG CLASS

  • Antibiotics
  • Mucolytics
  • Bronchodilators
  • Anti-inflammatory agents

GLOBAL BRONCHIECTASIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

  • Oral
  • Inhalation
  • Intravenous

GLOBAL BRONCHIECTASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL BRONCHIECTASIS DRUGS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bronchiectasis Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bronchiectasis Drugs Market Snippet by Drug Class
    • 2.1.2. Bronchiectasis Drugs Market Snippet by Route of Administration
    • 2.1.3. Bronchiectasis Drugs Market Snippet by Distribution Channel
    • 2.1.4. Bronchiectasis Drugs Market Snippet by Country
    • 2.1.5. Bronchiectasis Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Bronchiectasis Drugs Key Market Trends

  • 3.1. Bronchiectasis Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bronchiectasis Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bronchiectasis Drugs Market Opportunities
  • 3.4. Bronchiectasis Drugs Market Future Trends

4. Bronchiectasis Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bronchiectasis Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bronchiectasis Drugs Market Landscape

  • 6.1. Bronchiectasis Drugs Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bronchiectasis Drugs Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
    • 7.1.2. Antibiotics
    • 7.1.3. Mucolytics
    • 7.1.4. Bronchodilators
    • 7.1.5. Anti-inflammatory agents

8. Bronchiectasis Drugs Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
    • 8.1.2. Oral
    • 8.1.3. Inhalation
    • 8.1.4. Intravenous

9. Bronchiectasis Drugs Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Bronchiectasis Drugs Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Bronchiectasis Drugs Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Bronchiectasis Drugs Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Bronchiectasis Drugs Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Bronchiectasis Drugs Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Bronchiectasis Drugs Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Bronchiectasis Drugs Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. GlaxoSmithKline plc
    • 11.2.2. Novartis AG
    • 11.2.3. Pfizer Inc.
    • 11.2.4. AstraZeneca plc
    • 11.2.5. Boehringer Ingelheim International GmbH
    • 11.2.6. Roche Holding AG
    • 11.2.7. Teva Pharmaceutical Industries Ltd.
    • 11.2.8. Bayer AG
    • 11.2.9. Sanofi S.A.
    • 11.2.10. Sunovion Pharmaceuticals Inc.
    • 11.2.11. Mylan N.V.
    • 11.2.12. Cipla Ltd.
    • 11.2.13. Grifols S.A.
    • 11.2.14. Insmed Incorporated
    • 11.2.15. Arbor Pharmaceuticals LLC

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data Route of Administrations
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Bronchiectasis Drugs Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Bronchiectasis Drugs Market, by Drug Class 2018-2030 (USD Million)
  • TABLE Bronchiectasis Drugs Market: Route of Administration Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Route of Administration
  • TABLE Global Bronchiectasis Drugs Market, by Route of Administration 2018-2030 (USD Million)
  • TABLE Bronchiectasis Drugs Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Bronchiectasis Drugs Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Bronchiectasis Drugs Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Bronchiectasis Drugs Market, by Region 2018-2030 (USD Million)
  • TABLE North America Bronchiectasis Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Bronchiectasis Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Bronchiectasis Drugs Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE North America Bronchiectasis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Bronchiectasis Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Bronchiectasis Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Bronchiectasis Drugs Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Europe Bronchiectasis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bronchiectasis Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bronchiectasis Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bronchiectasis Drugs Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bronchiectasis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Bronchiectasis Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Bronchiectasis Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Bronchiectasis Drugs Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Latin America Bronchiectasis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bronchiectasis Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bronchiectasis Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bronchiectasis Drugs Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bronchiectasis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)